Agreement revolves around Factor VIII purification.



BAC and GE Healthcare will together develop and market affinity chromatography media for the purification of therapeutic recombinant Factor VIII.


BAC will provide its CaptureSelect® affinity ligands for  process-scale purification of FVIII for the prevention and treatment of bleeding in patients with haemophilia A.








This site uses Akismet to reduce spam. Learn how your comment data is processed.